Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 9/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901882 | 0.82 | GABRA1 (0.39) | GABRA1GABRB2AKR1B1PNMTTAAR1 | |
| SCHEMBL5573138 | 0.81 | MIF (0.49) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL1457250 | 0.81 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL25036351 | 0.75 | TAAR1 (0.50) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL2141390 | 0.74 | MIF (0.62) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL29616337 | 0.74 | MIF (0.62) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL3933178 | 0.73 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL2023050 | 0.71 | MIF (0.52) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL8348489 | 0.71 | GABRA1 (0.42) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL3069271 | 0.70 | PNMT (0.43) | CYP3A4AKR1B1PNMTTAAR1MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754768-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. | 2008-06-05 | — | — | US | disclosed |
| US-7335803-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1280524-B1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1280525-B1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030092766-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN SALES, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035178-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| US-6545182-B2 | For pain therapy | ALLERGAN SALES, INC. | 2003-04-08 | — | — | US | disclosed |
| EP-1280525-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1280524-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2003-02-05 | — | — | EP | disclosed |
| US-20020058839-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN SALES, INC. | 2002-05-16 | — | — | US | disclosed |
| US-6313172-B1 | ADMINISTERING HYDROXYETHYLTHIOUREA DERIVATIVE FOR THERAPY OF PAIN IN MAMMAL | ALLERGAN SALES, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001078702-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2001078703-A2 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058839-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ADRB2, ADRA2A, ADRA2C | MIF 3030/4885TRPA1 386/4885ALDH1A1 1420/4885 |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ADRB2, ADRA2A, ADRB1 | MIF 2568/4885TRPA1 303/4885ALDH1A1 1656/4885 |
| US-20030092766-A1 | Methods and compositions for modulating alpha adrenergic receptor activity | ADRB2, ADRA2A, ADRB1 | MIF 2568/4885TRPA1 303/4885ALDH1A1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.